arrow
J

James P Buteau

peter maccallum cancer center
H指数:19
被引数:1,942

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study

[177Lu]Lu-PSMA-617与pembrolizumab联合治疗转移性去势抵抗性前列腺癌(PRINCE):一项单臂、1b/2期研究

2026-03-300
OAAI
Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis

转移性去势抵抗性前列腺癌患者中初始影像和PSA变化对[177Lu]Lu-PSMA-617放射性药物治疗的预后价值:一项ProsTIC登记研究分析

2025-12-011
PRE
Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [68Ga]PSMA-11 or [18F]DCFPyL, [18F]FDG, and [177Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network
2025-11-010
PRE
Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617

基线和早期治疗时外周血循环肿瘤DNA比例是接受[177Lu]Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌的关键预后生物标志物

2025-10-290
OAAI
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial

镥-177 [177Lu]Lu-PSMA-I&T 联合镭-223 治疗转移性去势抵抗性前列腺癌(AlphaBet 研究):一项研究者发起、单中心、单臂、Ⅰ/Ⅱ期试验的期中分析

2025-10-180
PRE
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study

钽-161 [161Tb]Tb-PSMA-I&T双β–Auger放射性配体疗法在转移性去势抵抗性前列腺癌患者中的首次人体研究结果(VIOLET):一项单中心、单臂、I/II期研究

2025-07-030
PRE
Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate-to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA Study

在中位随访期研究中,[68Ga]Ga-PSMA-11 PET/CT检查显示前列腺腺癌活检证实的中危至高危患者体内低度摄取的患病率及中期结局

2025-03-270
PRE
PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL Study

PSMA引导的寡转移性肾细胞癌转移灶导向疗法:PEDESTAL概念验证研究

2025-02-200
PRE
Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer

LuCAB临床试验方案:一项评估卡巴他赛联合[177Lu]Lu-PSMA-617治疗转移性去势抵抗性前列腺癌的I-II期临床试验

2025-02-200
PRE
Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series

[177Lu]Lu-PSMA治疗后转移性去势抵抗性前列腺癌患者中的治疗相关髓系肿瘤:一个病例系列

2025-02-201
PRE
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial

[TheraP研究]:转移性去势抵抗性前列腺癌患者接受[177Lu]Lu-PSMA-617与卡巴他赛治疗疗效反应的预后和预测模型的验证——一项来自随机、开放标签、Ⅱ期临床试验的事后分析

2025-02-013
OAAI
Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial

中高危前列腺癌男性68Ga-PSMA-11正电子发射断层扫描/计算机断层扫描的基线淋巴结状态是治疗失败的预后因素: proPSMA试验的随访

2024-11-290
OAAI
Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer
2024-08-018
PRE
Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [161Tb]Tb-PSMA-I&T 161 Tb]Tb-PSMA-I&T

VIOLET的临床试验方案: [161 Tb] tb-psma-i & T转移性去势抵抗性前列腺癌患者放射配体治疗的单中心I/II期试验评估

2024-07-111
PRE
Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [ 68 Ga]Ga-PSMA-11 Positron Emission Tomography/ Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer

PRIMARY2的临床试验方案: 一项多中心,3期,随机对照试验,研究 [68 Ga]Ga-PSMA-11正电子发射断层扫描/计算机断层扫描对男性阴性或模棱两可的多参数磁共振成像诊断临床意义的前列腺癌的附加诊断价值

2024-06-017
OA
Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study
2024-03-0124
PRE